Source comparison
PT-141 Melanotan-2 Protocol Central + Peripheral: Research Application Comparison
Before selecting a peptide for your research protocol, compare receptor activity profiles and expected physiological outcomes: PT-141 (Bremelanotide) MC4R (selective) Increased sexual desire, arousal signaling through PVN and limbic pathways Minimal—no melanog
This comparison does not assign a generated winner or score.
- Before selecting a peptide for your research protocol, compare receptor activity profiles and expected physiological outcomes:
- PT-141 (Bremelanotide)
- MC4R (selective)
- Increased sexual desire, arousal signaling through PVN and limbic pathways
- Minimal—no melanogenesis, no direct erectile mechanism
- 1.75mg subcutaneous
- Onset 45–60 min, peak 2–3 hours, duration 6–8 hours
- Best choice for isolating CNS-mediated desire pathways without peripheral melanocortin activity—cleaner pharmacology for sexual behavior studies
- Melanotan-2
- MC1R, MC3R, MC4R, MC5R (non-selective)
- Sexual desire, appetite suppression through hypothalamic MC4R
- Melanogenesis (MC1R), spontaneous erections via nitric oxide (MC5R), increased sebum production
- 500mcg–1mg subcutaneous
- Onset 2–4 hours, peak 4–6 hours, duration 8–12 hours with melanogenic effects persisting weeks
- Produces overlapping central and peripheral effects—appropriate when investigating multi-system melanocortin activity but introduces confounds if isolating single pathways
- Alpha-MSH (endogenous reference)
- MC1R, MC3R, MC4R, MC5R (broad)
- Appetite regulation, fever modulation, limited sexual effects
- Melanogenesis, anti-inflammatory signaling
- N/A—endogenous peptide
- Constitutive receptor tone
- Neither PT-141 nor Melanotan-2 replicates endogenous alpha-MSH activity—both are synthetic analogs with altered selectivity